![ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆ - Annals of Oncology ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆ - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f34de229-a7f5-40ac-848d-fc87c7bb63db/gr3_lrg.jpg)
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆ - Annals of Oncology
![The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II - ESMO Open The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II - ESMO Open](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9187d6e4-45f0-4bc0-9ea7-5af371f6f3cf/gr1_lrg.jpg)
The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II - ESMO Open
![Biocytogen at the at the European Society for Medical Oncology (ESMO) 2018 annual meeting - Biocytogen Biocytogen at the at the European Society for Medical Oncology (ESMO) 2018 annual meeting - Biocytogen](https://biocytogen.com/content/uploads/2019/06/Munich-2018.png)
Biocytogen at the at the European Society for Medical Oncology (ESMO) 2018 annual meeting - Biocytogen
![ESMO 2019: Phase 3 Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Comprehensive Tumor Genomic and Transcriptomic Analyses ESMO 2019: Phase 3 Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Comprehensive Tumor Genomic and Transcriptomic Analyses](https://www.urotoday.com/images/ESMO2019_Sunitinib_Placebo.png)
ESMO 2019: Phase 3 Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Comprehensive Tumor Genomic and Transcriptomic Analyses
![Antonio Passaro MD PhD on Twitter: "#ESMO18 #LCSM Here one of the most terrific slide in this meeting. Officially, we have a new target TRK-fusion. Here the high activity of #Larotrectinib Do Antonio Passaro MD PhD on Twitter: "#ESMO18 #LCSM Here one of the most terrific slide in this meeting. Officially, we have a new target TRK-fusion. Here the high activity of #Larotrectinib Do](https://pbs.twimg.com/media/DqLAc1vW4AEqMg6.jpg)